Observational studyCancer medicine2026
Melanoma Brain Metastasis, Prognostic Factors, and Survival Outcomes After First Metastatic Line Therapy: A Monocentric Retrospective Study.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases (BMs) are a major cause of mortality in patients with melanoma. We conducted a retrospective observational study to identify prognostic factors for BM development and to evaluate the impact of first-line systemic therapy on BM occurrence and survival outcomes in patients with advanced melanoma. A total of 258 patients with unresectable Stage III or IV melanoma without BM at diagnosis were included and followed for BM occurrence. During a median follow-up of 8.7 years (95% CI, 7.0-10.6), 100 patients (38.8%) developed BM. Patients who developed BM were younger (median age 60.5 vs. 66 years; p = 0.008) and more frequently harbored a BRAF V600E/K mutation (51.4% vs. 48.6%; p < 0.001) compared with patients without BM, whereas ulceration status was similar between groups (p = 0.525). A mitotic rate ≥ 1 was more frequently observed in patients with BM (67.7% vs. 31.3%; p = 0.044). In multivariable logistic regression analyses, a high mitotic rate (≥ 6/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.